Managing Treatment Transitions During Cancer Care

Abstract

Treatment transitions are frequent, clinically complex points in the cancer care pathway. Patients may move from surgery to systemic therapy, from inpatient to outpatient services, between active treatment and surveillance, or from disease-directed therapy to symptom-focused and palliative care. Each transition creates potential for medication discrepancies, fragmented communication, delayed investigation, duplicative testing, inadequate symptom control, and avoidable distress. Safe transition management therefore requires coordinated multidisciplinary planning, accurate transfer of clinical information, shared decision-making, and timely follow-up. This review examines the disease burden associated with poorly coordinated transitions, the pathophysiological and treatment-related factors that increase vulnerability, clinical assessment requirements, evidence-informed management strategies, emerging technologies, and guideline-based recommendations. Particular attention is given to medication reconciliation, toxicity surveillance, treatment intent, patient education, psychosocial support, and integration of palliative care. A structured, risk-adapted approach can improve continuity, reduce preventable harm, and align treatment decisions with patient goals throughout the cancer trajectory.

Introduction

Cancer care increasingly involves multimodal treatment delivered across hospitals, outpatient clinics, community services, rehabilitation programs, and home settings. A single patient may encounter surgeons, medical oncologists, radiation oncologists, primary care clinicians, pharmacists, nurses, radiologists, pathologists, allied health professionals, and palliative care specialists. Transitions between these settings are not merely administrative events; they are periods in which the clinical plan, treatment intent, medication regimen, and responsibility for follow-up must be actively transferred. Failure at any point can compromise safety and undermine therapeutic benefit.

Treatment transitions occur after diagnosis, around operative care, during changes in systemic therapy, following treatment completion, at recurrence, and when care shifts toward palliation. They may be planned, such as a scheduled transition from neoadjuvant chemotherapy to surgery, or unplanned, such as an emergency admission for neutropenic fever. Effective transition management combines clinical precision with communication that is understandable to patients and caregivers. The central objective is to preserve continuity while adapting treatment to disease response, toxicity, comorbidity, patient preference, and changing goals of care.

Epidemiology / Disease Burden

The growing prevalence of cancer survivorship, increasing treatment complexity, and expansion of oral anticancer medicines have made transitions more common and more consequential. Patients frequently receive care from multiple institutions and may have incomplete access to prior imaging, pathology, molecular results, or treatment records. Older adults and people with advanced disease often experience repeated hospitalizations, emergency visits, and transfers between acute care, rehabilitation, home health, and hospice services.

Transition-related harm includes medication errors, omitted prophylaxis, duplicated therapy, inconsistent toxicity instructions, missed appointments, delayed recognition of recurrence, and failure to respond to abnormal laboratory results. The burden is not distributed equally. Patients with limited health literacy, language barriers, transportation difficulties, financial insecurity, cognitive impairment, or minimal caregiver support face increased risk. Ineffective transitions also increase clinician workload and may lead to avoidable hospital utilization, treatment interruptions, and reduced confidence in the healthcare system.

Pathophysiology

Although transition failure is primarily a systems problem, its clinical consequences are mediated by cancer biology and treatment-related physiology. Cytotoxic chemotherapy can produce myelosuppression, mucosal injury, nausea, renal dysfunction, and cumulative neuropathy. Immune checkpoint inhibitors may cause delayed immune-mediated toxicities involving the endocrine organs, liver, bowel, lungs, skin, heart, or nervous system. Targeted therapies can produce organ-specific adverse effects, while radiation may cause acute inflammation and late tissue injury. These toxicities may emerge after a patient has left the treatment center or changed providers.

Malnutrition, sarcopenia, chronic inflammation, impaired immunity, and reduced physiological reserve further increase vulnerability. Organ dysfunction can alter drug clearance and narrow the therapeutic index of anticancer agents. Disease progression may cause pain, obstruction, thrombosis, bleeding, infection, or neurologic compromise, creating rapidly changing clinical priorities. A safe transition must therefore transfer not only diagnoses and prescriptions but also the expected time course of toxicity, thresholds for urgent assessment, treatment intent, and the rationale for ongoing monitoring.

Risk Factors

Important risk factors include polypharmacy, recent hospitalization, complex chemotherapy protocols, oral anticancer treatment, immunotherapy, renal or hepatic impairment, frailty, advanced age, cognitive decline, and multiple chronic diseases. Patients transitioning after major surgery may have drains, wounds, ostomies, altered nutrition, or anticoagulation requirements. Those moving between institutions are at particular risk when electronic records are incompatible or when pathology and imaging are not transferred promptly.

Organizational risk factors include unclear ownership of follow-up, absent discharge summaries, poorly defined escalation pathways, inadequate pharmacist involvement, and communication limited to diagnosis codes rather than clinical reasoning. Social risk factors include inability to pay for medicines, unstable housing, limited internet access, low confidence in self-management, and caregiver exhaustion. Risk assessment should be performed before the transition and repeated when the clinical situation changes.

Clinical Features

Clinical features requiring attention depend on treatment modality and disease status. New fever, chills, hypotension, dyspnea, confusion, severe diarrhea, persistent vomiting, bleeding, rapidly worsening pain, or reduced urine output may indicate a medical emergency. Patients receiving immunosuppressive treatment may have serious infection without a prominent fever. Immune-mediated toxicities can present subtly with fatigue, weight change, diarrhea, cough, rash, jaundice, palpitations, or altered mental status.

At every transition, clinicians should assess symptom burden, functional status, nutritional intake, hydration, mood, sleep, cognition, and caregiver capacity. The assessment should distinguish expected treatment effects from signs of progression or serious toxicity. Clear written and verbal instructions should specify which symptoms require same-day contact, emergency evaluation, or routine review.

Diagnosis

Diagnostic evaluation during a transition begins with verification of the active cancer diagnosis, stage, biomarkers, prior treatments, response status, and current treatment intent. The receiving team should review operative reports, pathology, molecular testing, imaging, laboratory trends, allergies, adverse reactions, and relevant comorbidities. Medication reconciliation must include prescription drugs, over-the-counter products, supplements, anticoagulants, corticosteroids, analgesics, antiemetics, and medicines stopped during hospitalization.

Investigations should be guided by symptoms, treatment protocol, and organ risk rather than by indiscriminate testing. Complete blood counts, renal and hepatic profiles, endocrine tests, electrocardiography, imaging, or microbiological studies may be required before therapy is continued or modified. When records are incomplete, uncertainty should be documented explicitly and resolved before high-risk treatment proceeds whenever clinically feasible. Diagnostic communication should explain not only results but also their implications for the next treatment decision.

Treatment & Management

Management should begin with a structured transition plan prepared before the patient leaves a treatment setting. The plan should identify the diagnosis, current disease status, treatment intent, regimen and cycle dates, recent toxicities, pending tests, medication changes, central-line or wound care requirements, follow-up appointments, and responsible clinicians. A concise handoff between professionals should use a standardized format and include direct contact information for urgent questions.

Medication reconciliation is a core safety intervention. Each medicine should be classified as continued, discontinued, held, or newly prescribed, with the reason and duration documented. Oral anticancer medicines require assessment of adherence, access, interactions, administration with food, safe handling, and missed-dose instructions. Pharmacists can identify interactions involving anticoagulants, anticonvulsants, anti-infective drugs, acid-suppressive therapy, and complementary products.

Patient and caregiver education should use plain language, teach-back, and written action plans. Education must cover expected adverse effects, infection prevention, hydration, nutrition, reproductive considerations, driving or work restrictions, and when to seek urgent care. Follow-up should occur early after a high-risk transition, with review of symptoms, laboratory results, treatment tolerance, adherence, and psychosocial needs. Telehealth and telephone monitoring can support continuity when integrated with clear escalation pathways.

Transitions to survivorship care should include a treatment summary, surveillance schedule, late-effect risks, preventive care needs, rehabilitation recommendations, and identification of the clinician responsible for long-term monitoring. Transitions to palliative or hospice care should be framed as an active change in treatment goals rather than abandonment of care. Symptom control, advance care planning, caregiver support, and access to urgent advice should be addressed alongside decisions about anticancer therapy.

Recent Advances / Emerging Therapies

Digital oncology platforms increasingly support shared care plans, automated toxicity questionnaires, laboratory alerts, medication reconciliation, and remote symptom monitoring. Patient-reported outcome systems can identify clinically important deterioration before a scheduled visit, although alert fatigue and unequal digital access must be addressed. Interoperable electronic records and structured treatment summaries may reduce information loss between institutions.

Precision oncology adds another layer of transition complexity because molecular results may arrive after initial treatment decisions and can change therapy rapidly. Biomarker-directed treatments, antibody-drug conjugates, cellular therapies, and novel immunotherapies require specialized monitoring and coordinated management of delayed or uncommon toxicities. Multidisciplinary tumor boards, pharmacist-led clinics, nurse navigation, and transitional care programs can help integrate these developments. Future research should evaluate which combinations of digital monitoring, clinical navigation, and risk stratification produce durable improvements in safety and patient-centered outcomes.

Guideline Recommendations

Contemporary oncology and patient-safety guidance consistently supports early transition planning, standardized handoffs, medication reconciliation, patient engagement, and explicit assignment of follow-up responsibility. High-risk patients should receive individualized plans that account for treatment toxicity, comorbidity, functional status, health literacy, and social circumstances. Communication should occur promptly between the sending and receiving teams, and essential records should be available at the point of care.

Guideline-concordant practice also supports routine assessment of symptoms and distress, timely palliative care involvement for patients with substantial symptom burden or advanced disease, and survivorship planning after active treatment. Institutions should audit treatment delays, medication discrepancies, unplanned acute care use, missed follow-up, and patient understanding. Quality improvement should include patients and caregivers in the design of transition materials and should measure equity, not only overall performance.

Conclusion

Managing treatment transitions during cancer care is a clinical safety priority that requires more than the transfer of a discharge document. It involves preserving treatment intent, anticipating toxicity, reconciling medicines, communicating uncertainty, coordinating professionals, and preparing patients and caregivers to act appropriately. Risk-adapted planning is particularly important for older adults, people with advanced disease, patients receiving complex systemic therapies, and those facing social or logistical barriers. Standardized handoffs, pharmacist and nursing involvement, early follow-up, interoperable records, and integration of palliative and survivorship services can reduce preventable harm while improving continuity. As cancer treatment becomes more personalized and distributed across care settings, robust transition processes will remain essential to achieving safe, effective, and goal-concordant care.